“We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS.”

http://www.ncbi.nlm.nih.gov/pubmed/26535431

http://www.thctotalhealthcare.com/category/multiple-sclerosis-ms/